CA2873891C - Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders - Google Patents
Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders Download PDFInfo
- Publication number
- CA2873891C CA2873891C CA2873891A CA2873891A CA2873891C CA 2873891 C CA2873891 C CA 2873891C CA 2873891 A CA2873891 A CA 2873891A CA 2873891 A CA2873891 A CA 2873891A CA 2873891 C CA2873891 C CA 2873891C
- Authority
- CA
- Canada
- Prior art keywords
- melatonin
- memantine
- pharmaceutical composition
- composition according
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012121410 | 2012-05-24 | ||
| RU2012121410/15A RU2488388C1 (ru) | 2012-05-24 | 2012-05-24 | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
| PCT/RU2012/000888 WO2013176567A1 (ru) | 2012-05-24 | 2012-10-31 | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2873891A1 CA2873891A1 (en) | 2013-11-28 |
| CA2873891C true CA2873891C (en) | 2016-02-16 |
Family
ID=49155569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2873891A Expired - Fee Related CA2873891C (en) | 2012-05-24 | 2012-10-31 | Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150157604A1 (enExample) |
| EP (1) | EP2857011A4 (enExample) |
| JP (1) | JP5864819B2 (enExample) |
| KR (1) | KR101581611B1 (enExample) |
| CN (1) | CN104334166A (enExample) |
| AU (1) | AU2012380583B2 (enExample) |
| CA (1) | CA2873891C (enExample) |
| EA (1) | EA201400973A1 (enExample) |
| HK (1) | HK1205467A1 (enExample) |
| IL (1) | IL235852A0 (enExample) |
| IN (1) | IN2014DN09940A (enExample) |
| RU (1) | RU2488388C1 (enExample) |
| UA (1) | UA112352C2 (enExample) |
| WO (1) | WO2013176567A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2536270C1 (ru) * | 2013-10-21 | 2014-12-20 | Общество с ограниченной ответственностью ООО "ВАЛЕНТА ИНТЕЛЛЕКТ" | Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс |
| ES2943587T3 (es) | 2015-11-24 | 2023-06-14 | Massachusetts Inst Technology | Sistemas para prevenir, atenuar y/o tratar demencia |
| WO2018004391A1 (ru) * | 2016-06-29 | 2018-01-04 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина |
| RU2623865C1 (ru) * | 2016-06-29 | 2017-06-29 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина |
| RU2654713C1 (ru) * | 2016-06-29 | 2018-05-22 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина |
| US10849856B2 (en) | 2016-10-31 | 2020-12-01 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
| DK3337462T3 (da) | 2016-10-31 | 2020-10-12 | Neurim Pharma 1991 | Melatonin-minitabletter og fremgangsmåde til fremstilling heraf |
| KR102612531B1 (ko) | 2016-11-17 | 2023-12-12 | 코그니토 쎄라퓨틱스, 인코포레이티드 | 인지 기능 개선을 위한 시스템 |
| ES3058718T3 (en) | 2017-10-10 | 2026-03-12 | Massachusetts Inst Technology | Systems for preventing, mitigating, and/or treating dementia |
| US10960225B2 (en) | 2017-10-10 | 2021-03-30 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES413944A1 (es) | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| DE58905637D1 (de) | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie. |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US6469044B1 (en) | 1995-02-01 | 2002-10-22 | Neurim Pharmaceuticals (1991) Ltd. | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
| WO1999001416A2 (en) * | 1997-06-30 | 1999-01-14 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane nmda receptor antagonists |
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| US20050129783A1 (en) * | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| US7183321B2 (en) * | 2001-12-17 | 2007-02-27 | Bristol-Myers Squibb Company | Antidiabetic formulation and method |
| CN101897736A (zh) | 2002-10-30 | 2010-12-01 | Asat应用科学技术股份公司 | 含有褪黑素、银杏和生物素的制剂 |
| RU2268737C2 (ru) | 2004-02-16 | 2006-01-27 | Государственное учреждение институт клинической иммунологии СО РАМН | Способ лечения атопического дерматита |
| US8039009B2 (en) * | 2004-06-17 | 2011-10-18 | Forest Laboratories Holdings Limited | Modified release formulations of memantine oral dosage forms |
| EP1841460A2 (en) * | 2004-06-18 | 2007-10-10 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| AU2005286672B2 (en) * | 2004-09-23 | 2009-03-12 | Merz Pharma Gmbh & Co. Kgaa | Memantine for the treatment of childhood behavioral disorders |
| MY148806A (en) * | 2005-04-04 | 2013-05-31 | Takeda Pharmaceutical | Prophylactic or therapeutic agent for nocturnal conduct disorder associated with dementia |
| CN1709230A (zh) * | 2005-07-05 | 2005-12-21 | 北京阜康仁生物制药科技有限公司 | 盐酸美金刚分散片及其制备方法 |
| RU2294741C1 (ru) | 2005-08-08 | 2007-03-10 | Рина Михайловна Заславская | Способ лечения больных ишемической болезнью сердца, стабильной стенокардией в сочетании с артериальной гипертонией |
| KR20090024140A (ko) * | 2006-05-22 | 2009-03-06 | 반다 파마슈티칼즈, 인코퍼레이티드. | 우울증 질환에 대한 치료 |
| AU2007253684A1 (en) * | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
| EP1886670A1 (en) * | 2006-07-05 | 2008-02-13 | Teva Pharmaceutical Industries Ltd | Pharmaceutical compositions of memantine |
| WO2008005534A2 (en) * | 2006-07-06 | 2008-01-10 | Forest Laboratories, Inc. | Orally dissolving formulations of memantine |
| GB0623897D0 (en) * | 2006-11-30 | 2007-01-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutical composition of memantine |
| WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
| RU2326660C1 (ru) | 2007-03-14 | 2008-06-20 | Закрытое акционерное общество "Биологические исследования и системы" | Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты) |
| JP5600058B2 (ja) | 2007-04-11 | 2014-10-01 | ファーマシューティカル プロダクションズ, インコーポレイテッド | メラトニンタブレットならびに調剤及び使用方法 |
| US8728532B2 (en) | 2007-04-12 | 2014-05-20 | Regents Of The University Of Minnesota | Ischemia/reperfusion protection compositions and methods of using |
| US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| WO2010089132A1 (en) * | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| RU2394571C1 (ru) | 2009-05-14 | 2010-07-20 | Государственное бюджетное учреждение здравоохранения города Москвы "Городская клиническая больница № 24" Департамента здравоохранения города Москвы | Способ лечения воспалительных заболеваний кишечника |
| RU2418586C2 (ru) | 2009-06-11 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО НГМУ Росздрава) | Способ коррекции нарушений в репродуктивных органах, вызванных высокой температурой |
| RU2428183C1 (ru) | 2010-07-01 | 2011-09-10 | Рина Михайловна Заславская | Адаптоген для метеочувствительных больных стенокардией и артериальной гипертензией и применение мелатонина в качестве адаптогена |
-
2012
- 2012-05-24 RU RU2012121410/15A patent/RU2488388C1/ru not_active IP Right Cessation
- 2012-10-31 AU AU2012380583A patent/AU2012380583B2/en not_active Revoked
- 2012-10-31 IN IN9940DEN2014 patent/IN2014DN09940A/en unknown
- 2012-10-31 CN CN201280073167.XA patent/CN104334166A/zh not_active Withdrawn
- 2012-10-31 EA EA201400973A patent/EA201400973A1/ru unknown
- 2012-10-31 EP EP12877152.4A patent/EP2857011A4/en not_active Withdrawn
- 2012-10-31 CA CA2873891A patent/CA2873891C/en not_active Expired - Fee Related
- 2012-10-31 HK HK15106114.1A patent/HK1205467A1/xx unknown
- 2012-10-31 JP JP2015513964A patent/JP5864819B2/ja not_active Expired - Fee Related
- 2012-10-31 WO PCT/RU2012/000888 patent/WO2013176567A1/ru not_active Ceased
- 2012-10-31 US US14/400,526 patent/US20150157604A1/en not_active Abandoned
- 2012-10-31 UA UAA201412436A patent/UA112352C2/uk unknown
- 2012-10-31 KR KR1020147032836A patent/KR101581611B1/ko not_active Ceased
-
2014
- 2014-11-23 IL IL235852A patent/IL235852A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1205467A1 (en) | 2015-12-18 |
| RU2488388C1 (ru) | 2013-07-27 |
| EA201400973A1 (ru) | 2015-02-27 |
| JP2015517569A (ja) | 2015-06-22 |
| IN2014DN09940A (enExample) | 2015-08-14 |
| WO2013176567A1 (ru) | 2013-11-28 |
| JP5864819B2 (ja) | 2016-02-17 |
| KR101581611B1 (ko) | 2015-12-31 |
| CN104334166A (zh) | 2015-02-04 |
| US20150157604A1 (en) | 2015-06-11 |
| KR20150005999A (ko) | 2015-01-15 |
| IL235852A0 (en) | 2015-01-29 |
| EP2857011A4 (en) | 2015-12-02 |
| AU2012380583B2 (en) | 2015-01-22 |
| EP2857011A1 (en) | 2015-04-08 |
| UA112352C2 (uk) | 2016-08-25 |
| CA2873891A1 (en) | 2013-11-28 |
| AU2012380583A1 (en) | 2014-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2873891C (en) | Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders | |
| De Ponti | Pharmacology of serotonin: what a clinician should know | |
| EP3443987B1 (en) | A pharmaceutical composition for prevention of diet induced obesity | |
| US20220096491A1 (en) | Compositions and methods for treating alzheimer's disease and parkinson's disease | |
| EP4035668A1 (en) | Anticholinergic neuroprotective composition and methods | |
| EP3424499B1 (en) | A pharmaceutical composition for neuropathic pain | |
| CA3183560A1 (en) | Compositions and methods for treating alzheimer's disease and parkinson's disease | |
| KR102486126B1 (ko) | 알펠리십을 포함하는 제약 조성물 | |
| US20250152544A1 (en) | Sleep-improving compositions and methods of use | |
| US20260014098A1 (en) | Fenchol as a stimulator of free fatty acid receptor and other uses thereof | |
| CN114786647A (zh) | 口服药学立即释放组合物和用于重量减轻的治疗方法 | |
| WO2015060746A1 (ru) | Комбинация для лечения и/или профилактики проявлений психических, когнитивных, поведенческих и неврологических нарушений при органических заболеваниях цнс различного генеза | |
| JP2020511455A (ja) | 医薬組成物およびその使用 | |
| US9999614B2 (en) | Combination for the prophylaxis and treatment of behavioural, mental, and cognitive disorders | |
| JP2022526755A (ja) | 化合物バフィデムスタット(vafidemstat)などkdm1a阻害剤を使用した注意欠陥多動性障害の処置方法 | |
| CN121370879A (zh) | 治疗边缘型人格障碍的方法 | |
| CN107441105A (zh) | 人参二醇皂苷Rb组分在制备防治疼痛药物中的应用 | |
| CN111939139A (zh) | 一种盐酸美金刚缓释和盐酸多奈哌齐速释胶囊及其制备方法 | |
| KR20240070564A (ko) | 알츠하이머병 예방 또는 치료용 약학적 조성물 | |
| KR20220160269A (ko) | 갈라민트리에티오디드를 유효성분으로 포함하는 근육질환의 예방 또는 치료용 약학적 조성물 | |
| KR20220107597A (ko) | 인지 장애 예방 또는 개선용 조성물 | |
| CA3223922A1 (en) | Medicaments comprising glycosidase inhibitors | |
| JP2013049643A (ja) | 選択的セロトニン再取り込み阻害薬の誘発嘔吐に対する制吐剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150220 |
|
| MKLA | Lapsed |
Effective date: 20181031 |